FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. Presented are antibodies targeting integrin α2β1 containing humanised anti-integrin alpha-2 (α2) antibodies, as well as a method of treating by the integrin α2 antibodies. The humanised integrin α2 antibodies comprise a variable region of a light chain domain, a constant human light chain domain and a variable constant heavy chain domain of human IgG1, which exhibit the altered effector function. The variable constant heavy chain domain of human IgG1 comprises an S324N substitution. The invention can be used in medicine.
EFFECT: antibodies exhibit complement-dependent cytotoxicity, improved antibody-dependent cell-mediated cytotoxicity and improved CDC and ADCC.
33 cl, 3 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE OR PEPTIDE COMPLEX BINDING TO alpha2- INTEGRIN, METHODS FOR PRODUCTION AND USE THEREOF | 2011 |
|
RU2588668C2 |
| VERSIONS OF IMMUNOGLOBULINS AND ITS APPLICATION | 2003 |
|
RU2326127C2 |
| ANTIBODIES TO OX-2/CD200 AND THEIR APPLICATION | 2007 |
|
RU2520088C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2005 |
|
RU2384345C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| HUMANISED ANTIBODIES WITH INCREASED STABILITY | 2015 |
|
RU2684703C2 |
| VERSIONS OF IMMUNOGLOBULIN AND THEIR APPLICATION | 2009 |
|
RU2536937C2 |
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
